) In this application clinical and basic science investigators of The Ohio State University Comprehensive Cancer Center (OSUCCC) join together in a collaborative approach to the conduct of phase I trials of new cancer therapeutic agents and regiments. These investigators will cooperate closely with the Cancer Therapy Evaluation Program of the National Cancer Institute in correlative studies which will evaluate clinical outcomes in the context of basic science observations. The present proposal builds upon the strengths of the OSUCCC in conducting clinical trials with pertinent biologic measurements. Trials conducted under this proposal will emphasize those agents and regimens with which faculty of the OSUCCC have had prior preclinical experience and/or which the applicants identify as impacting on the cellular and molecular network under study in their laboratories. The choice of depsipeptide and halichondrin B for proposed phase I trials reflect those considerations. Thus, correlative studies for those two drugs involve t h e p harmacokinetic and pharmacoanalytic, the apoptosis and signal transduction, the microtubule, and the topoisomerase laboratories in in vivo and in vitro measurements. Other phase I trials will utilize the DNA repair, biological response modifier, immune response, pharmacodynamic, and cancer chemoprevention laboratories as appropriate for the new agent or regiment u n d er investigation. Pharmacokinetics will play a central role in interpretation of clinical and biologic end points. Data management and protocol compliance is enhanced by; computerized data and prospective protocol management system of proven value in the conduct of clinical trials. Patient numbers available for phase I trials coupled with the clinical and basic science collaborative research experience and expertise of this proposal's participants provide an effective means for bringing new cancer agents more rapidly to the cancer patient. Studies done under this proposal not only will advance new therapies from the bench to the bedside, but also will provide insights into cancer biology. These insights in turn will lead to more rational anticancer treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA076576-05
Application #
6497680
Study Section
Special Emphasis Panel (ZCA1-RLB-7 (O1))
Program Officer
Jensen, Leeann T
Project Start
1998-04-15
Project End
2003-01-31
Budget Start
2002-02-26
Budget End
2003-01-31
Support Year
5
Fiscal Year
2002
Total Cost
$384,566
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Mims, Alice S; Mishra, Anjali; Orwick, Shelley et al. (2018) A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. Haematologica 103:982-987
Sborov, Douglas W; Canella, Alessandro; Hade, Erinn M et al. (2017) A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leuk Lymphoma 58:2310-2318
Bertino, Erin M; McMichael, Elizabeth L; Mo, Xiaokui et al. (2016) A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer. Mol Cancer Ther 15:2244-50
Maddocks, Kami; Hertlein, Erin; Chen, Timothy L et al. (2016) A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma 57:2212-5
Canella, Alessandro; Cordero Nieves, Hector; Sborov, Douglas W et al. (2015) HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget 6:31134-50
Yeh, Yuh-Ying; Ozer, Hatice Gulcin; Lehman, Amy M et al. (2015) Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood 125:3297-305
Sborov, Douglas W; Benson, Don M; Williams, Nita et al. (2015) Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma. Br J Haematol 171:74-83
Yeh, Yuh-Ying; Chen, Rong; Hessler, Joshua et al. (2015) Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia. Oncotarget 6:2667-79
Maddocks, Kami; Wei, Lai; Rozewski, Darlene et al. (2015) Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). Am J Hematol 90:327-33
Sborov, Douglas W; Nuovo, Gerard J; Stiff, Andrew et al. (2014) A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. Clin Cancer Res 20:5946-55

Showing the most recent 10 out of 81 publications